299 related articles for article (PubMed ID: 34734032)
1. Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China.
Shi Y; Chen W; Zhang Y; Bo M; Li C; Zhang M; Li G
Ann Transl Med; 2021 Sep; 9(18):1480. PubMed ID: 34734032
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum
Cai Y; Hui W; Zhu M; Zhang M; Gao Z; Wu H
Front Oncol; 2021; 11():768035. PubMed ID: 34900717
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Zhao M; Shao T; Chi Z; Tang W
Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non-Small Cell Lung Cancer in the Irish Healthcare Setting.
Chu RW; Vegas García A; Hickey C; Power DG; Gorry C
Value Health; 2023 Mar; 26(3):402-410. PubMed ID: 36368626
[TBL] [Abstract][Full Text] [Related]
7. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
Wu B; Lu S
Transl Lung Cancer Res; 2020 Oct; 9(5):1770-1784. PubMed ID: 33209600
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis.
Chen X; Zhao M; Tian L
Front Pharmacol; 2023; 14():1119906. PubMed ID: 37021058
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
Zhou K; Jiang C; Li Q
Lung Cancer; 2019 Oct; 136():98-101. PubMed ID: 31476529
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T
J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
Li Y; Liang X; Yang T; Guo S; Chen X
Front Oncol; 2022; 12():878054. PubMed ID: 36226060
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M
J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729
[TBL] [Abstract][Full Text] [Related]
17. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X
Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis.
Liao M; Kang S
Expert Rev Pharmacoecon Outcomes Res; 2024 Jan; 24(1):161-166. PubMed ID: 37789675
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.
Zhang C; Liu Y; Tan J; Tian P; Li W
Front Oncol; 2023; 13():1093469. PubMed ID: 36998459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
